MX2017004213A - Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano. - Google Patents
Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano.Info
- Publication number
- MX2017004213A MX2017004213A MX2017004213A MX2017004213A MX2017004213A MX 2017004213 A MX2017004213 A MX 2017004213A MX 2017004213 A MX2017004213 A MX 2017004213A MX 2017004213 A MX2017004213 A MX 2017004213A MX 2017004213 A MX2017004213 A MX 2017004213A
- Authority
- MX
- Mexico
- Prior art keywords
- dprs
- antibody
- dpr
- human
- derived anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proveen anticuerpos específicos de repetición de dipéptido (DPR) derivados de humano novedosos así como variantes sintéticas y derivados biotecnológicos de los mismos, de preferencia capaces de unirse a DPRs de C9ORF72, así como métodos relacionados con lo mismo. También se describen pruebas, kits, y soportes sólidos relacionados con anticuerpos específicos para DPRs y proteínas de DPR tales como C9ORF72-DPRs. El anticuerpo de la presente invención se puede utilizar en composiciones farmacéuticas y de diagnóstico para inmunoterapia dirigida a proteína de DPR y en productos de diagnóstico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14187180 | 2014-09-30 | ||
EP15180310 | 2015-08-07 | ||
PCT/EP2015/072516 WO2016050822A2 (en) | 2014-09-30 | 2015-09-30 | Human-derived anti-dipeptide repeats (dprs) antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017004213A true MX2017004213A (es) | 2017-07-19 |
Family
ID=54238439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004213A MX2017004213A (es) | 2014-09-30 | 2015-09-30 | Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano. |
Country Status (17)
Country | Link |
---|---|
US (2) | US10392447B2 (es) |
EP (1) | EP3201228A2 (es) |
JP (3) | JP6637971B2 (es) |
KR (2) | KR20230104759A (es) |
CN (1) | CN108064248B (es) |
AU (2) | AU2015326911B2 (es) |
BR (1) | BR112017006598A2 (es) |
CA (1) | CA2960925A1 (es) |
CO (1) | CO2017002804A2 (es) |
IL (2) | IL278941B (es) |
MX (1) | MX2017004213A (es) |
MY (1) | MY180054A (es) |
NZ (1) | NZ729808A (es) |
PH (1) | PH12017500489A1 (es) |
SG (2) | SG11201701925XA (es) |
WO (1) | WO2016050822A2 (es) |
ZA (2) | ZA201701733B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
WO2014062691A2 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
WO2015054676A2 (en) | 2013-10-11 | 2015-04-16 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
WO2016050822A2 (en) | 2014-09-30 | 2016-04-07 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
CA3097872A1 (en) * | 2018-04-27 | 2019-10-31 | Biogen Ma Inc. | Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody |
EP3861007A4 (en) * | 2018-10-01 | 2022-07-13 | United Neuroscience | CONSTRUCTIONS OF PEPTIDE IMMUNOGENS DIRECTED AGAINST DIPEPTIDE REPEAT PROTEINS FROM C9ORF72 |
KR20210111242A (ko) | 2018-10-29 | 2021-09-10 | 바이오젠 엠에이 인코포레이티드 | 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 |
WO2020107037A1 (en) * | 2018-11-25 | 2020-05-28 | President And Fellows Of Harvard College | Compounds and methods for treating neurodegenerative diseases |
BR112021010660A2 (pt) | 2018-12-06 | 2021-08-24 | Biogen Ma Inc. | Proteína de neurofilamento para guiar intervenção terapêutica sobre esclerose lateral amiotrófica |
CN110470837B (zh) * | 2019-08-30 | 2022-09-16 | 苏州西山生物技术有限公司 | 利用猴srv病毒gp20蛋白检测猴srv病毒的方法及其试剂盒 |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
EP0362371A4 (en) | 1988-04-15 | 1990-10-24 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
JPH09506761A (ja) | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
ATE236987T1 (de) | 1992-11-13 | 2003-04-15 | Idec Pharma Corp | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
RO120148B1 (ro) | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
WO2000030680A1 (en) | 1998-11-23 | 2000-06-02 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
EP1340088B1 (en) | 2000-11-17 | 2007-01-17 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
EP1373321A2 (en) | 2001-01-29 | 2004-01-02 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US20100040606A1 (en) * | 2006-03-06 | 2010-02-18 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
EA029481B1 (ru) | 2007-01-05 | 2018-04-30 | Юнивэсэти Оф Цюрих | Способ получения человеческого рекомбинантного антитела, специфично связывающего вариант эндогенного белка, формирующий аномальные патологические белковые структуры путем агрегации, олигомеризации или образования фибрилл |
US8709382B2 (en) * | 2007-01-11 | 2014-04-29 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
US9023351B2 (en) * | 2007-11-26 | 2015-05-05 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses thereof |
EA201391248A1 (ru) * | 2011-03-01 | 2014-05-30 | Эмджен Инк. | Биспецифические связывающие агенты |
JP6177231B2 (ja) * | 2011-04-20 | 2017-08-09 | ゲンマブ エー/エス | Her2に対する二重特異性抗体 |
DK2710033T3 (da) * | 2011-05-17 | 2021-03-08 | Univ Rockefeller | Human immundefektvirus-neutraliserende antistoffer og fremgangsmåder til anvendelse deraf |
US9316640B2 (en) * | 2011-11-11 | 2016-04-19 | Alere San Diego, Inc. | Devices and methods for detection of Panton-Valentine Leukocidin (PVL) |
WO2014114303A1 (en) | 2013-01-22 | 2014-07-31 | Deutsches Zentrum Für Neurodegenerative Erkrankungen | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion |
HUE046434T2 (hu) * | 2013-01-22 | 2020-03-30 | Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V | Dipeptid-ismétlõdõ fehérjék terápiás célpontként neurodegeneratív betegségekben, hexanukleotid ismétlõdõ expanzióval |
EP2948471A4 (en) | 2013-01-24 | 2016-08-10 | Mayo Foundation | METHOD AND MATERIALS FOR DETECTING POSITIVE FRONTOTEMPORAL PAPER DEGENERATION BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION OR AMYOTROPHATE LATERAL SCLEROSIS BY C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION |
AU2014241078B2 (en) | 2013-03-14 | 2020-03-12 | University Of Florida Research Foundation, Inc. | Di-amino acid repeat-containing proteins associated with ALS |
WO2016050822A2 (en) | 2014-09-30 | 2016-04-07 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2015
- 2015-09-30 WO PCT/EP2015/072516 patent/WO2016050822A2/en active Application Filing
- 2015-09-30 BR BR112017006598A patent/BR112017006598A2/pt not_active Application Discontinuation
- 2015-09-30 IL IL278941A patent/IL278941B/en unknown
- 2015-09-30 KR KR1020237021848A patent/KR20230104759A/ko not_active Application Discontinuation
- 2015-09-30 EP EP15771953.5A patent/EP3201228A2/en active Pending
- 2015-09-30 CN CN201580064969.8A patent/CN108064248B/zh active Active
- 2015-09-30 NZ NZ729808A patent/NZ729808A/en unknown
- 2015-09-30 MY MYPI2017700811A patent/MY180054A/en unknown
- 2015-09-30 SG SG11201701925XA patent/SG11201701925XA/en unknown
- 2015-09-30 US US15/508,343 patent/US10392447B2/en active Active
- 2015-09-30 SG SG10201902850TA patent/SG10201902850TA/en unknown
- 2015-09-30 AU AU2015326911A patent/AU2015326911B2/en active Active
- 2015-09-30 CA CA2960925A patent/CA2960925A1/en active Pending
- 2015-09-30 KR KR1020177011599A patent/KR102594327B1/ko active IP Right Grant
- 2015-09-30 MX MX2017004213A patent/MX2017004213A/es unknown
- 2015-09-30 JP JP2017517086A patent/JP6637971B2/ja active Active
-
2017
- 2017-03-09 IL IL251081A patent/IL251081A0/en unknown
- 2017-03-09 ZA ZA2017/01733A patent/ZA201701733B/en unknown
- 2017-03-14 PH PH12017500489A patent/PH12017500489A1/en unknown
- 2017-03-24 CO CONC2017/0002804A patent/CO2017002804A2/es unknown
-
2018
- 2018-12-07 ZA ZA2018/08270A patent/ZA201808270B/en unknown
-
2019
- 2019-06-07 US US16/434,654 patent/US10961322B2/en active Active
- 2019-11-26 JP JP2019213035A patent/JP2020031660A/ja not_active Withdrawn
-
2021
- 2021-08-20 JP JP2021134979A patent/JP2021177788A/ja active Pending
- 2021-10-06 AU AU2021245147A patent/AU2021245147A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2015326911A1 (en) | 2017-03-30 |
CA2960925A1 (en) | 2016-04-07 |
JP2017538665A (ja) | 2017-12-28 |
BR112017006598A2 (pt) | 2018-04-17 |
PH12017500489A1 (en) | 2017-08-07 |
SG10201902850TA (en) | 2019-04-29 |
KR102594327B1 (ko) | 2023-10-27 |
US20200010567A1 (en) | 2020-01-09 |
JP2020031660A (ja) | 2020-03-05 |
SG11201701925XA (en) | 2017-04-27 |
ZA201701733B (en) | 2021-09-29 |
IL278941A (en) | 2021-01-31 |
CO2017002804A2 (es) | 2017-06-20 |
MY180054A (en) | 2020-11-20 |
CN108064248B (zh) | 2022-03-15 |
ZA201808270B (en) | 2022-04-28 |
AU2021245147A1 (en) | 2021-11-04 |
WO2016050822A3 (en) | 2016-06-02 |
CN108064248A (zh) | 2018-05-22 |
JP6637971B2 (ja) | 2020-01-29 |
NZ729808A (en) | 2022-02-25 |
EP3201228A2 (en) | 2017-08-09 |
US10961322B2 (en) | 2021-03-30 |
WO2016050822A2 (en) | 2016-04-07 |
IL278941B (en) | 2022-07-01 |
KR20170061702A (ko) | 2017-06-05 |
IL251081A0 (en) | 2017-04-30 |
JP2021177788A (ja) | 2021-11-18 |
US10392447B2 (en) | 2019-08-27 |
KR20230104759A (ko) | 2023-07-10 |
AU2015326911B2 (en) | 2021-07-08 |
US20170247471A1 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500489A1 (en) | Human-derived anti-dipeptide repeats (dprs) antibody | |
PH12021550083A1 (en) | Human anti-tau antibodies | |
ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
CO2018002446A2 (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
MX2020011312A (es) | Anticuerpo de repetición de dipéptidos (dpr) anti poliglicina-alanina (poli-ga) derivado de humanos. | |
WO2014200910A3 (en) | Bioinformatic processes for determination of peptide binding | |
MX2015003150A (es) | Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos. | |
MX2018008680A (es) | Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43). | |
MX2022003704A (es) | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. | |
MX345092B (es) | Anticuerpos anti-tau humanos,. | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
WO2018119425A3 (en) | Anti-lilrb3 antibodies and methods of use thereof | |
TW201613981A (en) | Compositions and methods for the diagnosis of rheumatoid arthritis | |
WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
GB2541596A (en) | Method and composition for determining specific antibody responses to species of filovirus | |
MX2016012986A (es) | Composiciones y metodos para identificar especies de ehrlichia. | |
EA201790433A1 (ru) | Происходящее от человека антитело к дипептидным повторам (dpr) | |
WO2016001424A3 (en) | Human-derived anti-human il-20 antibodies and assay for the identification of anti-cytokine antibodies |